Senna for Constipation: Positive Trials, an Uncertain Pooled Result

The Japanese trial measured overall improvement

A 2021 Japanese trial¹ enrolled 90 adults, mean age 42, with constipation lasting nearly ten years on average. 93% were women. For 28 days, participants received senna, magnesium oxide or placebo.¹

The paper reported overall improvement rates of 69.2% with senna and 11.7% with placebo. Bowel-movement frequency and constipation-related quality of life also favored senna. That is evidence of short-term benefit, but the primary outcome was a symptom-improvement rating. It should not be recast as a percentage permanently cured.¹

The Hong Kong trial defined success differently

A 2019 trial² enrolled 291 adults across eight Hong Kong clinics. It compared a Chinese herbal formula, senna and placebo over eight weeks. The senna regimen was reported as 15 mg daily.²

At week eight, 57.7% of the senna group and 33.0% of the placebo group met the trial’s definition of a complete response: at least one additional complete spontaneous bowel movement per week compared with baseline. The word “complete” in that outcome does not mean every constipation symptom disappeared.²

After another eight weeks of follow-up, response rates were 20.6% and 17.5%, respectively. The treatment-period percentages should not be presented as a lasting benefit after stopping.²

Combining positive trials can still leave uncertainty

The 2025 British Dietetic Association guideline³ pooled the senna-versus-placebo arms of those two trials: 254 participants, excluding the other treatment arms. Both trials individually favored senna, but their estimated effects differed substantially.³

The pooled response estimate was 2.78 times the placebo response, with a 95% confidence interval from 0.93 to 8.27. That range includes no advantage as well as a large benefit. The evidence was rated low certainty. Saying the pooled result was statistically uncertain preserves more of the finding than saying senna cannot work.³

Different response definitions also matter: a general improvement rating and one additional complete bowel movement are not identical targets.¹²

A recommendation still needs a plan for your product

The 2023 U.S. gastroenterology guideline conditionally suggests senna, with low certainty of evidence. Its senna analysis used one placebo-controlled trial. That recommendation and the British pooled result describe different assessments of a limited evidence base; neither establishes a universally effective regimen. The U.S. panel also notes that 83% of senna participants reduced their daily dose during the trial. Reported benefit does not mean everyone stayed on the starting dose.⁴

MedlinePlus⁵ advises speaking with a doctor before taking senna for more than one week. Cramps and stomach discomfort can occur. Stop and call a doctor for rectal bleeding; if senna does not produce a bowel movement, talk to a doctor before taking more.⁵

Bring the exact product and your medicine list to a pharmacist or clinician. Ask what improvement to track, how to respond to cramps or loose stools, and when to review treatment. The study percentages cannot choose those instructions for you.

The “What the Pharmacy Shelf Offers” section of Bloated by Dinner discusses the two guidelines’ differing senna findings and questions to take to the pharmacy. The laxative-aisle guide places senna alongside other constipation treatments.